The company will use the financing to support clinical trials focusing on Parkinson’s, amyotrophic lateral sclerosis and schizophrenia.
The expansion brings the company’s total series B financing round to $116 million, according to a Feb. 13 Cerevance news release provided to Becker’s.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
